EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Annexin Pharmaceuticals AB's Enterprise Value is €6.85 Mil.
Annexin Pharmaceuticals AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.57 Mil. Therefore, Annexin Pharmaceuticals AB's EV-to-FCF for today is -1.92.
The historical rank and industry rank for Annexin Pharmaceuticals AB's EV-to-FCF or its related term are showing as below:
FRA:Q910'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.95 Med: 0 Max: 0
Current: -1.95
FRA:Q910's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 16.48
vs FRA:Q910: -1.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Annexin Pharmaceuticals AB (FRA:Q910) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Annexin Pharmaceuticals AB's PE Ratio (TTM) for today is calculated as:
Annexin Pharmaceuticals AB's share price for today is €1.16.
Annexin Pharmaceuticals AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.540.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Annexin Pharmaceuticals AB EV-to-FCF Related Terms
Annexin Pharmaceuticals AB EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:Q910 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Annexin Pharmaceuticals AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexin Pharmaceuticals AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Annexin Pharmaceuticals AB's EV-to-FCF falls into.
Annexin Pharmaceuticals AB's current Enterprise Value is €6.85 Mil.
Annexin Pharmaceuticals AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexin Pharmaceuticals AB (FRA:Q910) has a EV-to-FCF of -1.92 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Annexin Pharmaceuticals AB and its competitors. According to the industry distribution chart, Annexin Pharmaceuticals AB ranks #999999 out of 331 companies in the Biotechnology industry.
Is Annexin Pharmaceuticals AB's EV-to-FCF too high?
Annexin Pharmaceuticals AB's current EV-to-FCF is -1.92. Based on the distribution chart, Annexin Pharmaceuticals AB ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annexin Pharmaceuticals AB ranks #999999 out of 331 companies for EV-to-FCF. This places Annexin Pharmaceuticals AB in the lower half of its industry. The industry median EV-to-FCF is 16.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.48, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Annexin Pharmaceuticals AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annexin Pharmaceuticals AB's current EV-to-FCF is -1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (FRA:Q910) has a current EV-to-FCF of -1.92. The current EV-to-FCF is -1.92. Annexin Pharmaceuticals AB's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (FRA:Q910), the current EV-to-FCF is -1.92 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
13GF Score
Get the complete analysis for FRA:Q910
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q910 has been successfully added to your 
